Endocrine effects of the H2-receptor antagonists cimetidine and ranitidine.
This paper reviews investigations on the endocrine effects of two H2-receptor antagonists, cimetidine and ranitidine. Cimetidine has hyperprolactinaemic properties and interferes with the peripheral activity of the sexual hormone (DHT) and probably with the pituitary LH secretion. A possible effect on TSH and thyroid hormone secretion or peripheral metabolism is suggested. Ranitidine seems to have no central or peripheral effects (after both acute and chronic administration) on sexual hormones. High doses (300 mg i.v. bolus) of the drug induce a significant increase in prolactin basal levels, whereas no effects follow oral administration. The effects on PRL are sex-related and less marked than those obtained with cimetidine. The chronic administration of this drug does not affect basal or TRH-stimulated PRL levels. No effects were apparent on TSH serum levels after either oral or i.v. acute administration, whereas lower basal and TRH-stimulated T4 values were registered after chronic treatment. On the basis of these results, a possible interference of ranitidine on iodothyronine metabolism can be suggested.
D000818:Animals; D002927:Cimetidine / Q000494:pharmacology*; D012739:Gonadal Steroid Hormones / Q000378:metabolism; D006062:Gonadotropins / Q000378:metabolism; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D011388:Prolactin / Q000378:metabolism; D011899:Ranitidine / Q000494:pharmacology*; D013963:Thyroid Hormones / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism
D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D006728:Hormones; D013963:Thyroid Hormones; D002927:Cimetidine; D011899:Ranitidine; D011388:Prolactin; D013972:Thyrotropin